Bio

Lindsay Martin, MSN, AGNP-C, AOCNP is a nurse practitioner specializing in head and neck and endocrine malignancies. She began her career as a registered nurse at Stamford Hospital in Stamford, CT after graduated from New York University. She worked on an inpatient oncology and palliative care unit before transitioning to outpatient cancer care. She joined Mount Sinai Hospital as a nurse clinical coordinator within the Genitourinary Oncology practice while pursuing her master's degree from Hunter College. After becoming a board-certified nurse practitioner, she remained within the GU program until 2021, when she took over the GU Cancer Clinical Trials program as a program manager and sub-investigator. Her supervisory scope expanded in 2024 when she became the nurse leader for nurses and APPs within the Solid Tumor Clinical Trials service line. Seeking to grow as a nurse leader and expand her scope of expertise, she joined Stanford Health Care in August 2025 as the Lead Advanced Practice Provider for the Head and Neck, Cutaneous and Endocrine department. She is passionate about reducing healthcare disparities and improving access to quality cancer care through care coordination.

Clinical Focus

  • Nurse Practitioner
  • Head and Neck Oncology
  • Endocrine Oncology
  • Cutaneous Oncology

Professional Education

  • AGNP-C, American Academy of Nurse Practitioners Certification Board, Adult-Gerontology Primary Care Nurse Practitioner (AGNP)
  • AOCNP, Oncology Nursing Certification Corporation, Advanced Oncology Certified Nurse Practitioner (AOCNP®)
  • MSN, Hunter College, Adult-Gerontology Nurse Practitioner (2018)
  • BSN, New York University, Nursing (2013)
  • BS, University of Rhode Island, Kinesiology (2011)

Additional Info

  • Other ID(s):
    S0395347
    LinMartin
  • Email:
    lindsaymartin@stanfordhealthcare.org

Links

All Publications

  • A Pilot Study of the Combination of 5-Azacitidine and All-trans Retinoic Acid in Biochemically Recurrent Prostate Cancer. medRxiv : the preprint server for health sciences Patel, V. G., Singh, D. K., Joshi, H., Sherpa, N., Liaw, B., Tsao, C. K., Galsky, M. D., Diamond, L., Lopez-Anton, M., Sosa, M. S., Aguirre-Ghiso, J. A., Oh, W. K. 2025

    Abstract

    Despite definitive local therapy, some men with prostate cancer develop biochemical recurrence (BCR-PCa) and progress to metastatic disease. Current standard-of-care, androgen receptor pathway inhibitors (ARPIs) with or without androgen deprivation therapy (ADT) carry substantial long-term morbidity. This trial tested a novel, non-hormonal approach of 5-azacitidine (AZA) plus all-trans retinoic acid (ATRA) to induce tumor cell dormancy via epigenetic reprogramming. The regimen was well tolerated, with manageable toxicities, and showed preliminary signals of delayed PSA progression and prolonged PSA doubling time in some patients, suggesting dormancy induction. One patient achieved durable disease stabilization with ATRA maintenance. These first-in-human findings indicate that epigenetic reprogramming may modulate dormancy in BCR-PCa, offering a potential strategy to delay or minimize ADT use and its toxicities. This approach highlights the translational potential of preventing or delaying overt metastases by activating dormancy pathways in early recurrent prostate cancer.Biochemical recurrence (BCR) after definitive local therapy remains a major clinical challenge in prostate cancer (PCa), with heterogeneous disease trajectories and few established strategies to delay further progression without prolonged androgen deprivation. This pilot study evaluated the combination of 5-azacitidine (AZA) and all-trans retinoic acid (ATRA) to induce tumor dormancy and delay clinical progression in patients with BCR.In a prospective, open-label, randomized, single-institution pilot trial, patients with BCR of PCa and no recent hormonal or definitive therapy received low-dose AZA and sequential ATRA. The co-primary endpoints were changes in prostate-specific antigen doubling time (PSADT) and time to next treatment (TTNT). Safety and biomarker analyses, including bone morphogenetic protein (BMP) signaling and dormancy marker NR2F1 in circulating tumor cells (CTCs), were evaluated to investigate treatment effects on minimal residual disease dormancy.Fourteen patients were enrolled. Treatment resulted in an increase in median PSADT from 2.45 to 4.56 months. The median TTNT was 9.6 months, with 28.6% of patients experiencing TTNT over 12 months. No new safety signals were identified; adverse events were consistent with those expected for AZA and ATRA. Analysis of circulating BMP4 and BMP7 suggested that higher BMP4 levels may correlate with treatment response. Notably, all patients achieved testosterone recovery post-treatment, likely reflecting the avoidance of ongoing androgen deprivation. Across the cohort, treatment with AZA+ATRA led to a reduction in total CTC numbers and an apparent increase in the fraction of NR2F1-positive CTCs in responders, although the small cohort size limited statistical testing.The combination of AZA and ATRA was feasible and prolonged PSA kinetics in a subset of patients with BCR of PCa, with a favorable safety profile. This epigenetic approach promoting tumor dormancy presents a potential strategy to defer progression and delay the need for continuous hormonal suppression. Larger studies are warranted to validate these findings and further explore biomarkers predictive of clinical benefit.

    View details for DOI 10.1101/2025.08.11.25333316

    View details for PubMedID 40832381

    View details for PubMedCentralID PMC12363707